VEGF inhibitors can increase the risk of heart failure, coronary artery disease, hypertension, and thromboembolic diseases through mechanisms such as endothelial injury, vasoconstriction and remodeling, inflammatory response, and platelet activation (Porta and Striglia, 2020; Chen et al., 2018). The gene discussed is VEGFA; the disease is Hypertension.